The short version of pineal peptides fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-20 and is reviewed periodically as new material appears.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.
The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
Typical storage for the lyophilized powder is −20 °C or lower, in a sealed container protected from light and moisture. Hygroscopic material should be allowed to equilibrate to room temperature before the vial is opened, which limits condensation on the contents. Working solutions are commonly divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. Dilute solutions are more prone to adsorption onto plastic surfaces and to loss during filtration, so procedures that minimize transfers and use low-binding labware are preferable.
Reversed-phase high-performance liquid chromatography is the standard approach for assessing purity, usually with ultraviolet detection near 214 nm, where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the molecular mass and helps reveal truncation or deletion byproducts. Amino acid analysis can verify composition, and counterion content is sometimes measured because peptides purified with trifluoroacetic acid retain variable amounts of that salt. Purity figures reported without a stated method and detection wavelength are difficult to interpret.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Calculated from the four residues with three water losses |
| Molecular mass | About 390.35 g/mol | Monoisotopic mass near 390.14, used for mass-spectrometric identification |
| Peptide sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG; no disulfide bonds or modified residues |
| Appearance | White to off-white solid | Supplied as a dried powder |
| Isoelectric point | Around 4 | Estimated from aspartate and glutamate side-chain pKa values |
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
=== Pharmacodynamics === SR-17018 acts as a biased partial agonist of the μ-opioid receptor (MOR), with strong selectivity for activation of G protein signaling over β-arrestin2 recruitment. Its affinities (Ki) for the human opioid receptors have been reported to be 11 nM for the MOR, 68 nM for the κ-opioid receptor (KOR), and >10,000 nM for the δ-opioid receptor (DOR). In terms of MOR activation, the drug had activational potencies and efficacies (EC50Tooltip half-maximal effective concentration and EmaxTooltip maximal efficacy) of 97–193 nM (72–75%) for GTPγS binding, 76 nM (105%) for cAMPTooltip cyclic adenosine monophosphate accumulation, and >10,000 nM (10%) for β-arrestin2 recruitment. Both GTPγS binding and cAMP accumulation are measures of G protein signaling. The drug showed a calculated bias factor for GTPγS binding over β-arrestin2 recruitment of 80 to 100 relative to DAMGO. SR-17018 also showed strong bias for G protein activation over β-arrestin2 recruitment using mouse proteins, albeit with reduced efficacy for GTPγS binding (Emax = 37%). β-Arrestin2 activation may contribute to opioid tolerance, though it is not the only mechanism of tolerance to these drugs. SR-17018 shows a strikingly different MOR phosphorylation profile from other MOR biased, partial, and full agonists. Additional studies have characterized the interactions of SR-17018 with the MOR, including activational potencies and efficacies at downstream signaling pathways, as well.
Tafasitamab, sold under the brand name Monjuvi, is an anti-cancer medication used in combination with lenalidomide for the treatment of adults with diffuse large B-cell lymphoma; or, when used in combination with lenalidomide and rituximab, for the treatment of follicular lymphoma. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody. Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite. Tafasitamab was approved for medical use in the United States in July 2020, and in the European Union in August 2021. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Triosephosphate isomerase rapidly interconverts dihydroxyacetone phosphate with glyceraldehyde 3-phosphate (GADP) that proceeds further into glycolysis. This is advantageous, as it directs dihydroxyacetone phosphate down the same pathway as glyceraldehyde 3-phosphate, simplifying regulation.
Polonium is "distinctly metallic" in some ways. Both of its allotropic forms are metallic conductors. It is soluble in acids, forming the rose-coloured Po2+ cation and displacing hydrogen: Po + 2 H+ → Po2+ + H2. Many polonium salts are known. The oxide PoO2 is predominantly basic in nature. Polonium is a reluctant oxidizing agent, unlike its lightest congener oxygen: highly reducing conditions are required for the formation of the Po2− anion in aqueous solution. Whether polonium is ductile or brittle is unclear. It is predicted to be ductile based on its calculated elastic constants. It has a simple cubic crystalline structure. Such a structure has few slip systems and "leads to very low ductility and hence low fracture resistance". Polonium shows nonmetallic character in its halides, and by the existence of polonides. The halides have properties generally characteristic of nonmetal halides (being volatile, easily hydrolyzed, and soluble in organic solvents). Many metal polonides, obtained by heating the elements together at 500–1,000 °C, and containing the Po2− anion, are also known.
Sources: en.wikipedia.org
=== Diversity and inclusion campaigns === Cave's ethnic origins have been the subject of debate. She has been featured in Diversity Campaigns by MTV, ABC's Good Morning America, SXSW, 100 Top Women in the World List, The Why Culture, and The Color of STEM.
Emopamil binding protein is a protein that in humans is encoded by the EBP gene, located on the X chromosome. EBP was discovered through its high-affinity binding to anti-ischemic drugs such as emopamil, from which it also derives its name. In addition to emopamil, EBP also bind with high affinity a variety of structurally unrelated compounds, such as amiodarone, opipramol, ifenprodil, trifluoperazine, and chlorpromazine. EBP has a mass of 27.3 kDa and resembles the σ2-receptor that resides in the endoplasmic reticulum of various tissues as an integral membrane protein.
Dorothy Hodgkin on Nobelprize.org including the Nobel Lecture, 11 December 1964 The X-ray Analysis of Complicated Molecules Portraits of Dorothy Hodgkin at the National Portrait Gallery, London Works by or about Dorothy Hodgkin at the Internet Archive Four interviews with Dorothy Crowfoot Hodgkin recorded between 1987 and 1989 in partnership with the Royal College of Physicians are held in the Medical Sciences Video Archive in the Special Collections at Oxford Brookes University: Professor Dorothy Crowfoot Hodgkin OM FRS in interview with Sir Gordon Wolstenholme: Interview 1 (1987). Professor Dorothy Crowfoot Hodgkin OM FRS in interview with Max Blythe: Interview 2 (1988). Professor Dorothy Crowfoot Hodgkin OM FRS in interview with Max Blythe: Interview 3 (1989). Professor Dorothy Crowfoot Hodgkin OM FRS at home talking with Max Blythe: Interview 4 (1989). Watch a lecture of Dorothy Crowfoot Hodgkin (1910–1994) at the 1988 Nobel Laureates Symposium at the annual meeting of the American Crystallographic Association, Philadelphia Dorothy Hodgkin featured on the BBC Radio 4 program In Our Time on 3 October 2019. "The exceptional life of Dorothy Crowfoot Hodgkin", BBC "Ideas" video, 27 September 2021
==== Non-Hodgkin lymphoma ==== Results from several studies indicate that, compared to other autoimmune diseases, Sjögren's disease is associated with a notably high incidence of non-Hodgkin lymphoma, a cancer of white blood cells. About 5% of patients with Sjögren's develop some form of lymphoid malignancy. Patients with severe cases are much more likely to develop lymphomas than patients with mild or moderate cases. The most common lymphomas are salivary extranodal marginal zone B cell lymphomas (MALT lymphomas in the salivary glands) and diffuse large B-cell lymphoma. Lymphomagenesis in primary Sjögren's disease patients is considered a multistep process, with the first step being chronic stimulation of autoimmune B cells, especially B-cells that produce rheumatoid factor at sites targeted by the disease. This increases the frequency of oncogenic mutation, leading to any dysfunction at checkpoints of autoimmune B-cell activation to transform into malignancy. A study's findings concluded that continuous stimulation of autoimmune B cells leads to subtle germinal abnormalities in genes having specific consequences in B cells, which underlie the susceptibility to lymphoma.
CREST is not easily diagnosed as it closely mimics symptoms of other connective tissue and autoimmune diseases. Diagnoses are usually given when a patient presents two or more of the five major clinical symptoms. Additionally, blood can be tested for positive ANA and ACA, and skin biopsies can be taken to help confirm a diagnosis.
Sources: en.wikipedia.org
No. Epithalamin is a peptide-containing extract of bovine pineal glands, while epitalon is a single synthetic tetrapeptide. The extract contains many peptides and other tissue components, so its composition varies between batches in ways that a synthesised sequence does not.
It is not recognised as an endogenous peptide hormone. The four-residue sequence can appear inside larger proteins and in digestive fragments of dietary protein, but no dedicated pathway producing it as a signalling molecule has been identified.
Several cell-culture reports describe increased telomerase activity after treatment, measured by enzyme assays or by transcript levels. Results differ between cell types and laboratories, and measured telomere lengthening has been reported in some studies but not in others, which leaves the physiological relevance open.
The powder is normally kept at −20 °C or below in a sealed, moisture-protected container. Letting the vial reach room temperature before opening helps prevent condensation on the contents.